CLINICAL TRIALS PROFILE FOR SIBUTRAMINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for SIBUTRAMINE HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00037752 ↗ | Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates | Completed | National Heart, Lung, and Blood Institute (NHLBI) | N/A | 2002-09-01 | The purpose of this study is to determine if sibutramine will decrease post-cessation weight gain and cigarette smoking in overweight and obese smokers who quit smoking. |
| NCT00037752 ↗ | Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates | Completed | University of Tennessee | N/A | 2002-09-01 | The purpose of this study is to determine if sibutramine will decrease post-cessation weight gain and cigarette smoking in overweight and obese smokers who quit smoking. |
| NCT00044187 ↗ | The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder | Completed | Eli Lilly and Company | Phase 4 | 2001-04-01 | Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity. In this study, the Anti-obesity Agent is being tested to see if it can treat weight gain that may be associated with taking olanzapine. The purposes of this study are to determine the safety of olanzapine when given in combination with the Anti-obesity Agent and any side effects that might be associated with it and whether weight-gain agent can help treat weight gain that may be associated with taking olanzapine. |
| NCT00134199 ↗ | A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects | Completed | Pfizer | Phase 2/Phase 3 | 2005-03-01 | To evaluate the effect of 6-month administration of CP-945,598 on: - weight loss and waist circumference, - blood pressure, cholesterol, glucose - other biochemical variables like insulin, leptin, ghrelin, adiponectin, PAI 1, TNF-α and hsCRP - the relationship between the concentration of the drug on the blood and the above parameters - physical and psychosocial functioning, weight related symptoms, treatment satisfaction, appetite/hunger/satiety/craving and mood, anxiety, anhedonia and depression |
| NCT00212173 ↗ | Adolescent Weight Management Study | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | N/A | 1969-12-31 | Protocol #1:The goals of this study was to examine whether increased weight loss in obese adolescent is induced when the weight loss medication sibutramine is added to a family-based, behavioral weight control program. Protocol #2: This study aims to improve the behavioral treatment of obesity during adolescence. A behavioral program using regular foods will be compared to a behavioral program using a structured meal plan (a portion-controlled approach with liquid-meal replacements [nutritional supplements]). This structured approach may be better for the promotion of weight loss compared to a diet of regular foods. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SIBUTRAMINE HYDROCHLORIDE
Condition Name
Clinical Trial Locations for SIBUTRAMINE HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for SIBUTRAMINE HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for SIBUTRAMINE HYDROCHLORIDE
Sponsor Name
